NIH awards $5.4M grant for Phase II trial of Alzheimer's therapy

11/5/2008 | RedOrbit

The University of California, San Diego, has received a $5.4 million grant from the NIH's National Institute of Aging to conduct a Phase II clinical trial of Ceregene's CERE-110 -- a gene-therapy product that delivers nerve-growth factor in patients with Alzheimer's disease. Cergene said it expects the trial, which will involve 50 Alzheimer's patients in several clinical sites across the country, to begin early next year.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
Minneapolis, MN
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
In house Compliance Officer
Pompano Beach, FL